All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

BCL-2 inhibitors

BCL-2 inhibitors

Bcl-2 is a pro-survival oncogene that promotes leukemogenesis by blocking programmed cell death. Therefore, agents designed to disrupt proteins that are involved in anti-apoptotic pathways are considered for AML therapy, including Bcl-2 inhibitors like venetoclax. For other pro-apoptotic proteins, like 'BH3-only' proteins, BH3 agonists are in development.


All Interventions